Ryan Scott

The FDA approved the denosumab biosimilars Enoby and Xtrenbo for patients on hormone therapies for breast or prostate cancer that weaken bones.

Tamara Mobley shares how persistent back pain led to her myeloma diagnosis and why she now raises awareness to help others recognize subtle warning signs.

Cancer during pregnancy is rare but increasingly recognized as maternal age rises and non-invasive prenatal testing becomes more common.

Lymphoma is a treatable cancer of the immune system; early diagnosis and personalized treatment with chemo and radiation often lead to a cure.

The FDA granted priority review to an sBLA for first-line treatment with Enhertu plus Perjeta in unresectable or metastatic HER2-positive breast cancer.

Dr. Ravi Munver sat down for an interview with CURE to discuss progress in kidney cancer care.

The U.S. FDA has granted fast track designation to the investigational therapy MNV-201 for the treatment of myelodysplastic syndrome.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments.

The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like breast and prostate cancer.

Researchers have created a novel immunotherapy for metastatic kidney cancer that could provide a new treatment option for patients with limited options.

Bob Lane, a prostate cancer survivor, discusses the stigma men often feel when talking about prostate cancer.

Dr. Prithviraj Bose explains how doctors tailor myelofibrosis treatments and how patients can work with their care teams to navigate options.

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma.

Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes.

Your diagnosis of an early-stage blood cancer, such as a MPN or MDS, means that something has changed in the way your bone marrow produces blood cells.

GLP-1a treatment in patients with polycythemia vera was linked to significant reductions in mortality, disease progression, and serious complications.

The FDA granted two fast track designations to TT125-802, an investigational therapy, for the treatment of advanced/metastatic non-small cell lung cancer.

In August 2025, the FDA approved various anti-cancer treatments across a range of disease types, such as colorectal, lung cancer and brain cancer.

Clara Mae Cirk, a 30-year-old diagnosed with stage 4 lung cancer, shares how cancer has reshaped her perspective on strength and self-care.

Women with HR+ early breast cancer who paused endocrine therapy to become pregnant breastfed without increased risk of recurrence in the short term.

Kimberly (Cary) Demirhan concludes a three-part series on bringing cancer research to the community setting.

Women diagnosed with ovarian cancer should consult a fertility specialist immediately, as egg or embryo freezing is most effective before treatment starts.

Dr. Monica Avila explains how cancer treatments can trigger early menopause, causing symptoms like hot flashes, mood changes and irregular periods.

FDA grants D3S-001 treatment breakthrough therapy for KRAS G12C some with lung cancer and orphan drug status for KRAS G12C colorectal cancer in adults.

Stage 1 melanoma is treatable with surgery, and when combined with early detection, proper care and regular follow-ups, it offers a favorable outlook.

Clara Mae Cirk, a 30-year-old who was diagnosed with stage 4 lung cancer, opens up about her journey and using social media as an outlet to educate others.

The FDA has granted fast track designation to stenoparib, an investigational therapy for patients with advanced ovarian cancer.

Rina-S earned breakthrough therapy designation for patients with advanced endometrial cancer whose disease has worsened after platinum-based chemotherapy.

The FDA has granted rusfertide breakthrough therapy designation for patients with polycythemia vera, a step that could speed its path to approval.